Ms Grahn was most recently vice president of clinical operations at MedGenesis Therapeutix. At Horizon, Ms Grahn will lead all clinical operations activities. Ms Grahn has a master’s degree in biochemistry from Illinois Institute of Technology in Chicago and a bachelor’s degree in chemistry and biology from Knox College in Galesburg, Illinois.
Mr Duncan was a co-founder of Corus Pharma, which was purchased by Gilead Sciences, and was most recently vice president of operations at Corus.
At Horizon, Mr Duncan will lead all manufacturing, quality control and supply chain activities. Mr Duncan has a bachelor’s degree in biology from Trent University in Ontario, Canada.
Timothy Walbert, president and chief executive officer of Horizon Therapeutics, said: “Amy and Iain bring valuable operations experience that is vital as we prepare regulatory filings in the US and Europe and move forward with the anticipated commercialization of our lead product candidate, HZT-501. During their respective careers, Amy and Iain have been instrumental in the growth of start-up as well as established biotech and pharmaceutical companies and their leadership will be an important part of Horizon’s future growth.”